Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory Board
Xilis expands CAB to five members to help company develop its MicroOrganoSphere technology
Durham, N.C. -- Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB).
Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He served as the past President of American Society of Clinical Oncology (ASCO) from 2015 to 2018 and is a world-recognized thought leader in the field of breast cancer.
Dr. Hayes will become the fifth member of the Xilis CAB, joining leading gastrointestinal (GI) oncologists Scott Kopetz, MD, PhD, FACP, MD Anderson and Tanios Bekaii-Saab, MD, Mayo Clinic, along with Xilis’ lung and early clinical phase oncologists and investigators Gilberto de Lima Lopes, Jr., MD, MBA, FAMS, University of Miami and Scott Antonia, MD, PhD, Duke University. These leading oncologists are providing guidance to introduce Xilis’ MOS technology to the clinic.
“The addition of Dan Hayes to our CAB highlights the excitement of building our MOS technology across important tumor types. To have five of the world’s leading oncologists recognize the potential of our MOS technology to revolutionize the way we approach cancer therapy is gratifying,” said David Hsu, MD, co-founder of Xilis. “The chance to improve patients’ treatments is what motivates each of the clinicians on our board, which aligns with the passion of every employee at Xilis. Dan’s impact on the field of oncology cannot be overstated.”
Dr. Hayes joins an accomplished CAB with expertise in colon, breast, and lung cancers, as well as immuno-therapies.
About Xilis
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and supports drug discovery and development for pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up development and clinical trials of cancer drugs by enabling analysis of authentic tumor microenvironments, high-throughput preclinical modeling, and clinical patient selection capabilities.
-
Most popular related searches
Customer comments
No comments were found for Xilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory Board. Be the first to comment!